Advertisement

Analysis of HER-2/neu Receptor Expression and the Level of Neuronal Apoptosis in HER-2/neu Transgenic Mice during Aging

  • A. S. Solovyova
  • Yu. O. Sokolova
  • V. N. Anisimov
  • E. D. BazhanovaEmail author
BIOGERONTOLOGY
  • 11 Downloads

We studied neuronal death in the sensorimotor cortex, hippocampus, and supraoptic and paraventricular nuclei of the hypothalamus and dynamics of HER-2/neu expression in late ontogenesis in young and old transgenic HER-2/neu mice. Wild-type FVB/N mice served as the control. The intensity of apoptosis (TUNEL) and HER-2/neu expression (Western blotting) in the same brain regions were measured. HER-2/neu was detected in the cortex, hippocampus, and hypothalamus of transgenic and wild-type mice, and its expression increased with age. The effect of HER-2/neu on the intensity of cell death in various brain regions depended on the stage of ontogenesis and animal genotype. Enhanced expression of HER-2/neu determines low rate of cell death in the studied brain regions during pathological ageing.

Key Words

HER-2/neu aging sensorimotor cortex hippocampus hypothalamus 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bazhanova ED, Anisimov VN. The role of STAT transcription factors in apoptosis regulation of hypothalamic neurons in aging in HER-2/neu transgenic mice and wild-type FVB/N mice. Dokl. Biochem. Biophysics. 2016;468(1):217-219.CrossRefGoogle Scholar
  2. 2.
    Bazhanova ED, Kozlova YO, Anisimov VN, Sukhanov DS, Teply DL. Pharmacological correction of the apoptosis level in cortical neurons of ageing HER2/neu transgenic mice. J. Evol. Biochem. Physiol. 2016;52(1):64-73.CrossRefGoogle Scholar
  3. 3.
    Bazhanova ED, Kozlova YuO, Anisimov VN, Sukhanov DS, Teply DL. Pathways of neuronal apoptosis and functionality of the brain cortex during aging - the role of some drugs (angiogen, cytoflavin, piracetam). Patol. Fiziol. Eksp. Ter. 2016;60(2):13-19. Russian.Google Scholar
  4. 4.
    Bazhanova ED. Effects of exogenous neurometabolites on AKT- and ERK-signaling apoptotic pathways in the cortical neurons in the physiological and pathological (HER2/neu overexpression) aging. FEBS J. Suppl. 2017;284(Suppl. 1):252.Google Scholar
  5. 5.
    Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J. Gastroenterol. 2006;12(21):3297-3305.CrossRefGoogle Scholar
  6. 6.
    Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv. Anat. Pathol. 2014;21(2):100-107.CrossRefGoogle Scholar
  7. 7.
    Mattson MP. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 2000;1(2):120-129.CrossRefGoogle Scholar
  8. 8.
    Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell. Mol. Life Sci. 2004;61(23):2965-2978.CrossRefGoogle Scholar
  9. 9.
    Nelson EL. HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium. Clin. Invest. 2014;4(7):649-671.CrossRefGoogle Scholar
  10. 10.
    Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3(6):385-389.CrossRefGoogle Scholar
  11. 11.
    Panchenko AV, Popovich IG, Trashkov AP, Egormin PA, Yurova MN, Tyndyk ML, Gubareva EA, Artyukin IN, Vasiliev AG, Khaitsev NV, Zabezhinski MA, Anisimov VN. Biomarkers of aging, life span and spontaneous carcinogenesis in the wild-type and HER-2 transgenic FVB/N female mice. Biogerontology. 2016;17(2):317-324.CrossRefGoogle Scholar
  12. 12.
    Semenchenko GV, Anisimov VN, Yashin AI. Stressors and antistressors: how do they influence life span in HER-2/neu transgenic mice? Exp. Gerontol. 2004;39(10):1499-1511.CrossRefGoogle Scholar
  13. 13.
    Sun Z, Shi Y, Shen Y, Cao L, Zhang W, Guan X. Analysis of different HER-2 mutations in breast cancer progression and drug resistance. J. Cell. Mol. Med. 2015;19(12):2691-2701.CrossRefGoogle Scholar
  14. 14.
    Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br. J. Cancer. 2003;89(5):899-906.CrossRefGoogle Scholar
  15. 15.
    Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin. Oncol. 2003;30(5, Suppl. 16):38-48.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. S. Solovyova
    • 1
  • Yu. O. Sokolova
    • 2
  • V. N. Anisimov
    • 3
  • E. D. Bazhanova
    • 2
    • 4
    • 5
    Email author
  1. 1.Department of Chemistry and Molecular Biology, Chemistry and Biology ClusterSt. Petersburg National Research University of Information Technology, Mechanics and Optics (ITMO University)St. PetersburgRussia
  2. 2.Laboratory of Comparative Biochemistry of Cell FunctionI. M. Sechenov Institute of Evolutionary Physiology and BiochemistrySt. PetersburgRussia
  3. 3.Department of Carcinogenesis and Oncogerontology, N. N. Petrov National Medical Research Center of OncologyMinistry of Health of the Russian FederationSt. PetersburgRussia
  4. 4.Laboratory of Apoptosis Role in Development of Neuroendocrine SystemAstrakhan State UniversityAstrakhanRussia
  5. 5.Laboratory of Morphology and Electron Microscopy, Institute of ToxicologyFederal Medical-Biological AgencySt. PetersburgRussia

Personalised recommendations